JP7408008B2 - 抗アルファ－４－ベータ－７抗体 - Google Patents

抗アルファ－４－ベータ－７抗体 Download PDF

Info

Publication number
JP7408008B2
JP7408008B2 JP2023502654A JP2023502654A JP7408008B2 JP 7408008 B2 JP7408008 B2 JP 7408008B2 JP 2023502654 A JP2023502654 A JP 2023502654A JP 2023502654 A JP2023502654 A JP 2023502654A JP 7408008 B2 JP7408008 B2 JP 7408008B2
Authority
JP
Japan
Prior art keywords
cells
human
antibody
hiv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023502654A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022016198A5 (enExample
JP2023535556A (ja
Inventor
ミン，ジン
ン，イォク－チャン
ベナトゥイル，ロレンゾ
ビクスビー，ジャクリーヌ
デフチャー，タチャーナ
ドン，フェン
エルナンデス・ジュニア，アクセル
クリシュナン，プリーシ
ルゥ，リヤンジュイン
メンサ，フェデリコ
ミラー，レニー
サフ，ガウタム
Original Assignee
アッヴィ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッヴィ・インコーポレイテッド filed Critical アッヴィ・インコーポレイテッド
Publication of JP2023535556A publication Critical patent/JP2023535556A/ja
Publication of JPWO2022016198A5 publication Critical patent/JPWO2022016198A5/ja
Priority to JP2023212722A priority Critical patent/JP7765447B2/ja
Application granted granted Critical
Publication of JP7408008B2 publication Critical patent/JP7408008B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
JP2023502654A 2020-07-16 2021-07-16 抗アルファ－４－ベータ－７抗体 Active JP7408008B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023212722A JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ－４－ベータ－７抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052933P 2020-07-16 2020-07-16
US63/052,933 2020-07-16
PCT/US2021/070898 WO2022016198A1 (en) 2020-07-16 2021-07-16 Anti-αlpha-4-βeta-7 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023212722A Division JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ－４－ベータ－７抗体

Publications (3)

Publication Number Publication Date
JP2023535556A JP2023535556A (ja) 2023-08-18
JPWO2022016198A5 JPWO2022016198A5 (enExample) 2023-11-09
JP7408008B2 true JP7408008B2 (ja) 2024-01-04

Family

ID=77338969

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502654A Active JP7408008B2 (ja) 2020-07-16 2021-07-16 抗アルファ－４－ベータ－７抗体
JP2023212722A Active JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ－４－ベータ－７抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023212722A Active JP7765447B2 (ja) 2020-07-16 2023-12-18 抗アルファ－４－ベータ－７抗体

Country Status (15)

Country Link
US (2) US11639390B2 (enExample)
EP (1) EP4182349A1 (enExample)
JP (2) JP7408008B2 (enExample)
KR (1) KR20230038728A (enExample)
CN (1) CN115867352A (enExample)
AR (1) AR122983A1 (enExample)
AU (1) AU2021307468A1 (enExample)
CA (1) CA3188739A1 (enExample)
CO (1) CO2023001066A2 (enExample)
IL (1) IL299767A (enExample)
MX (1) MX2023000732A (enExample)
TW (1) TWI889871B (enExample)
UY (1) UY39327A (enExample)
WO (1) WO2022016198A1 (enExample)
ZA (1) ZA202300222B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202504919A (zh) 2023-05-30 2025-02-01 美商派拉岡醫療公司 α4β7整合素抗體組合物及使用方法
WO2025038861A1 (en) * 2023-08-15 2025-02-20 Abbvie Inc. Methods of treating human immunodeficiency virus (hiv) disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1135498B1 (en) 1998-11-18 2008-01-23 Genentech, Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AP2015008338A0 (en) * 2012-09-26 2015-04-30 Kflp Biotech Llc Compounds for the treatment and prevention of retroviral infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chang Li et al.，VIROLOGICA SINICA，2014年，Vol. 29, Issue 6，pp. 381-392
Mathieu Uzzan et al.，Sci. Transl. Med.，2018年，Vol. 10, article eaau4711，pp. 1-15
Michael C. Sneller et al.，Sci. Transl. Med.，2019年，Vol. 11, article eaax3447，pp. 1-8

Also Published As

Publication number Publication date
MX2023000732A (es) 2023-02-13
CA3188739A1 (en) 2022-01-20
JP7765447B2 (ja) 2025-11-06
UY39327A (es) 2022-02-25
CN115867352A (zh) 2023-03-28
BR112023000718A2 (pt) 2023-02-07
KR20230038728A (ko) 2023-03-21
EP4182349A1 (en) 2023-05-24
ZA202300222B (en) 2023-09-27
CO2023001066A2 (es) 2023-02-06
US20220017624A1 (en) 2022-01-20
US11639390B2 (en) 2023-05-02
TWI889871B (zh) 2025-07-11
TW202216781A (zh) 2022-05-01
AU2021307468A1 (en) 2023-02-02
JP2024037932A (ja) 2024-03-19
AR122983A1 (es) 2022-10-19
IL299767A (en) 2023-03-01
WO2022016198A1 (en) 2022-01-20
US20260062488A1 (en) 2026-03-05
JP2023535556A (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
CN111138542B (zh) 双特异性抗体及其用途
JP2023105024A (ja) 抗体およびその使用方法
JP6867955B2 (ja) 抗ｏｘ４０抗体及びその使用方法
JP5933646B2 (ja) ヒトｎｋｇ２ｄに対する抗体とその使用
CN111788225A (zh) 抗cd38抗体及与抗cd3和抗cd28抗体的组合
US20260062488A1 (en) Anti-alpha-4-beta-7 antibodies
JP2019522961A (ja) Ｔｌ１ａ抗体およびその使用
JP2020508637A (ja) 新規抗ｃｔｌａ４抗体
KR20210089143A (ko) 항-tnfr2 항체 및 그의 용도
US12227580B2 (en) Antigen binding molecules that bind LIGHT
GB2566389B (en) Antigen binding molecules that bind light
CA3196493A1 (en) B and t lymphocyte attenuator (btla) modulators and method of using same
US20240425603A1 (en) Anti-vegfr1 antibodies and their uses
BR122024013054A2 (pt) Anticorpo monoclonal humano anti-alfa-4--beta-7
BR112023000718B1 (pt) Anticorpo monoclonal anti-alfa-4-beta-7 humano
CN116685603A (zh) B和t淋巴细胞衰减因子（btla）调节剂及其使用方法
EA048894B1 (ru) Антитела к l1cam и их применение
HK1165813B (en) Anti cxcr4 antibodies for the treatment of hiv
HK1165813A1 (en) Anti cxcr4 antibodies for the treatment of hiv

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231031

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231219

R150 Certificate of patent or registration of utility model

Ref document number: 7408008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150